Research
Steroid-free medication for uveitis and uveitic glaucoma
A steroid-free eyedrop medication for uveitis and uveitic glaucoma patients, TRS01, is undergoing clinical investigation (as of May 2022). TRS01 is intended as an anti-inflammatory medication for uveitis and uveitic glaucoma that is not anticipated to contribute to elevated intraocular pressure and glaucoma. Up to May 2022, two Phase I/II clinical trials testing TRS01 have been completed. Several dozen patients have undergone these trials. TRS01 is now being investigated in a Phase III clinical trial in patients with noninfectious anterior uveitis, including some with uveitic glaucoma. == References ==
Olopatadine/mometasone, sold under the brand name Ryaltris, is a fixed-dose combination medication for the treatment of allergic rhinitis and rhinoconjunctivitis in adults and adolescents twelve years of age and older. It contains olopatadine hydrochloride and mometasone furoate monohydrate. It is sprayed into the nose.Common side effects include an unpleasant taste (dysgeusia).It was approved for medical use in Australia in December 2019, and in the United States in January 2022. References
External links
"Olopatadine". Drug Information Portal. U.S. National Library of Medicine. "Mometasone furoate". Drug Information Portal. U.S. National Library of Medicine. Clinical trial number NCT02631551 for "Efficacy and Safety of Fixed Dose Combination GSP 301 Nasal Spray (NS) in the Treatment of Seasonal Allergic Rhinitis (SAR) (GSP 301-301)" at ClinicalTrials.gov
Clinical trial number NCT02870205 for "Efficacy and Safety of GSP 301 Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (SAR) (GSP 301-304)" at ClinicalTrials.gov